Chinese patent medicine for promoting gastrointestinal motility and its preparation method

Abstract

The invention discloses a Chinese patent medicine for promoting gastrointestinal motility. The Chinese patent medicine is made from the following raw materials by weight: 9-18 parts of purslane, 15-28 parts of ovateleaf knotweed rhizome, 12-22 parts of radix aucklandiae, 8-17 parts of Mangnolia officinalis, 12-18 parts of aconite, 9-20 parts of perilla powder, 10-25 parts of securinega suffruticosa, 8-15 parts of Pericarpium Arecae, 2-4 parts of fritillary flowers, 8-14 parts of Evodia lepta, and 6-14 parts of herba belladonnae. The components of the Chinese patent medicine provided in the invention come from common traditional Chinese medicines, and are mostly edible medicinal products. With the characteristics of cheap raw materials, simple preparation and convenient use, the Chinese patent medicine is proved to have significant efficacy on irritable bowel syndrome, functional dyspepsia, functional abdominal bloating, functional constipation and other gastrointestinal functional lesions after many years of clinical application and pharmacological study. The raw material drugs together play a role in helping digestion and harmonizing stomach, descending the adverse-rising qi and arresting vomiting, promoting the circulation of qi and removing stagnation, soothing liver and descending qi, and can reach a good curative effect on gastroenteritis caused by various causes.

Description

technical field [0001] The invention relates to a Chinese patent medicine for promoting gastrointestinal motility and a preparation method thereof, belonging to the field of traditional Chinese medicine. Background technique [0002] Gastrointestinal functional lesions are caused by disorders of neuromuscular tissue control in the gastrointestinal tract, and are mainly manifested by gastrointestinal symptoms such as pantothenic acid, abdominal distension, constipation, and diarrhea, and there are no structural or biochemical changes in routine examinations. Such as irritable bowel syndrome, functional dyspepsia, etc., are common clinical diseases. Decreased gastrointestinal motility is one of the main manifestations of gastrointestinal functional lesions, and clinical symptoms such as abdominal distension and constipation may appear. At present, there are four generations of gastrointestinal motility drugs commonly used clinically. The first generation, such as metoclopram...

AI Technical Summary

Problems solved by technology

The second-generation prokinetic drug is domperidone, which is a peripheral dopamine receptor blocker. It is widely used clinically, mainly to promote gastric motility, but the effect of promoting intestinal motility is not good.

The third generation is cisapride, which is a kind of mehydroclopramide that replaces the alkylated benzodiazepines in its chemical structure. However, in recent years, it has been clinically found that Q-T interval prolongation or torsades de pointes can occur in patients with high sensitivity to cisapride. Tachycardia, for its further clinical application, there is still a lot of controversy

Relatively safe, common adverse reactions include gastric or eso